Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, RxSight Inc’s stock clocked out at $16.62, up 1.84% from its previous closing price of $16.32. In other words, the price has increased by $1.84 from its previous closing price. On the day, 0.97 million shares were traded. RXST stock price reached its highest trading level at $16.73 during the session, while it also had its lowest trading level at $15.84.
Ratios:
To gain a deeper understanding of RXST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.65 and its Current Ratio is at 12.68. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On April 15, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $18.
UBS Downgraded its Buy to Neutral on April 09, 2025, while the target price for the stock was maintained at $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Fountain Tamara sold 7,000 shares for $25.71 per share. The transaction valued at 180,002 led to the insider holds 24,793 shares of the business.
TAMARA R FOUNTAIN bought 7,000 shares of RXST for $180,002 on Mar 12 ’25. On Jan 22 ’25, another insider, Maniar Shweta, who serves as the Director of the company, sold 3,519 shares for $30.87 each. As a result, the insider received 108,618 and left with 7,383 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXST now has a Market Capitalization of 675386944 and an Enterprise Value of 458087616. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.55 while its Price-to-Book (P/B) ratio in mrq is 2.42. Its current Enterprise Value per Revenue stands at 3.089 whereas that against EBITDA is -13.623.
Stock Price History:
The Beta on a monthly basis for RXST is 1.32, which has changed by -0.7309809 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, RXST has reached a high of $64.50, while it has fallen to a 52-week low of $12.53. The 50-Day Moving Average of the stock is -9.42%, while the 200-Day Moving Average is calculated to be -54.73%.
Shares Statistics:
It appears that RXST traded 1.01M shares on average per day over the past three months and 1298830 shares per day over the past ten days. A total of 40.59M shares are outstanding, with a floating share count of 38.04M. Insiders hold about 6.40% of the company’s shares, while institutions hold 91.99% stake in the company. Shares short for RXST as of 1745971200 were 4279705 with a Short Ratio of 4.22, compared to 1743379200 on 3145063. Therefore, it implies a Short% of Shares Outstanding of 4279705 and a Short% of Float of 11.06.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of RxSight Inc (RXST) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.05, with high estimates of $0.01 and low estimates of -$0.24.
Analysts are recommending an EPS of between $0.06 and -$0.74 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is $0.07, with 6.0 analysts recommending between $0.56 and -$0.9.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $39.78M. It ranges from a high estimate of $41.6M to a low estimate of $38.8M. As of the current estimate, RxSight Inc’s year-ago sales were $34.89MFor the next quarter, 10 analysts are estimating revenue of $40.54M. There is a high estimate of $41.8M for the next quarter, whereas the lowest estimate is $38.9M.
A total of 11 analysts have provided revenue estimates for RXST’s current fiscal year. The highest revenue estimate was $189.51M, while the lowest revenue estimate was $161.72M, resulting in an average revenue estimate of $167.56M. In the same quarter a year ago, actual revenue was $139.93MBased on 11 analysts’ estimates, the company’s revenue will be $202.61M in the next fiscal year. The high estimate is $240.8M and the low estimate is $185.31M.
